214 related articles for article (PubMed ID: 32543950)
1. Drug delivery to macrophages: a review of nano-therapeutics targeted approach for inflammatory disorders and cancer.
Mukhtar M; Ali H; Ahmed N; Munir R; Talib S; Khan AS; Ambrus R
Expert Opin Drug Deliv; 2020 Sep; 17(9):1239-1257. PubMed ID: 32543950
[TBL] [Abstract][Full Text] [Related]
2. Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages.
Lee WH; Loo CY; Traini D; Young PM
Expert Opin Drug Deliv; 2015 Jun; 12(6):1009-26. PubMed ID: 25912721
[TBL] [Abstract][Full Text] [Related]
3. Targeting Macrophages as a Potential Therapeutic Intervention: Impact on Inflammatory Diseases and Cancer.
Ponzoni M; Pastorino F; Di Paolo D; Perri P; Brignole C
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29973487
[TBL] [Abstract][Full Text] [Related]
4. Targeted drug delivery to macrophages.
Jain NK; Mishra V; Mehra NK
Expert Opin Drug Deliv; 2013 Mar; 10(3):353-67. PubMed ID: 23289618
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery systems for biological therapies of inflammatory diseases.
Tran TH; Amiji MM
Expert Opin Drug Deliv; 2015 Mar; 12(3):393-414. PubMed ID: 25366552
[TBL] [Abstract][Full Text] [Related]
6. Recent Trends in Nanotechnology-Based Drugs and Formulations for Targeted Therapeutic Delivery.
Iqbal HMN; Rodriguez AMV; Khandia R; Munjal A; Dhama K
Recent Pat Inflamm Allergy Drug Discov; 2017; 10(2):86-93. PubMed ID: 27978790
[TBL] [Abstract][Full Text] [Related]
7. Nanosize drug delivery system.
Mukherjee B
Curr Pharm Biotechnol; 2013; 14(15):1221. PubMed ID: 25106648
[TBL] [Abstract][Full Text] [Related]
8. Mitochondria and neurodegenerative diseases: the promising role of nanotechnology in targeted drug delivery.
Pezzini I; Mattoli V; Ciofani G
Expert Opin Drug Deliv; 2017 Apr; 14(4):513-523. PubMed ID: 27467010
[TBL] [Abstract][Full Text] [Related]
9. Inflammation targeted nanomedicines: Patents and applications in cancer therapy.
Praveen TK; Gangadharappa HV; Abu Lila AS; Moin A; Mehmood K; Krishna KL; Hussain T; Alafnan A; Shakil S; Rizvi SMD
Semin Cancer Biol; 2022 Nov; 86(Pt 2):645-663. PubMed ID: 35405339
[TBL] [Abstract][Full Text] [Related]
10. pH-sensitive nano-systems for drug delivery in cancer therapy.
Liu J; Huang Y; Kumar A; Tan A; Jin S; Mozhi A; Liang XJ
Biotechnol Adv; 2014; 32(4):693-710. PubMed ID: 24309541
[TBL] [Abstract][Full Text] [Related]
11. Nasal-nanotechnology: revolution for efficient therapeutics delivery.
Kumar A; Pandey AN; Jain SK
Drug Deliv; 2016; 23(3):681-93. PubMed ID: 24901207
[TBL] [Abstract][Full Text] [Related]
12. Drug delivery to macrophages: Challenges and opportunities.
Pei Y; Yeo Y
J Control Release; 2016 Oct; 240():202-211. PubMed ID: 26686082
[TBL] [Abstract][Full Text] [Related]
13. Cell-mediated drug delivery.
Batrakova EV; Gendelman HE; Kabanov AV
Expert Opin Drug Deliv; 2011 Apr; 8(4):415-33. PubMed ID: 21348773
[TBL] [Abstract][Full Text] [Related]
14. Macrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases.
Singh A; Talekar M; Raikar A; Amiji M
J Control Release; 2014 Sep; 190():515-30. PubMed ID: 24747762
[TBL] [Abstract][Full Text] [Related]
15. Exploiting the cancer niche: Tumor-associated macrophages and hypoxia as promising synergistic targets for nano-based therapy.
Silva VL; Al-Jamal WT
J Control Release; 2017 May; 253():82-96. PubMed ID: 28285930
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy.
Qiu Q; Li C; Song Y; Shi T; Luo X; Zhang H; Hu L; Yan X; Zheng H; Liu M; Liu M; Liu M; Yang S; Liu X; Chen G; Deng Y
Acta Biomater; 2019 Jul; 92():184-195. PubMed ID: 31108259
[TBL] [Abstract][Full Text] [Related]
17. Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases.
Talekar M; Tran TH; Amiji M
AAPS J; 2015 Jul; 17(4):813-27. PubMed ID: 25921939
[TBL] [Abstract][Full Text] [Related]
18. Patenting of nanopharmaceuticals in drug delivery: no small issue.
du Toit LC; Pillay V; Choonara YE; Pillay S; Harilall SL
Recent Pat Drug Deliv Formul; 2007; 1(2):131-42. PubMed ID: 19075880
[TBL] [Abstract][Full Text] [Related]
19. Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.
Dobrovolskaia MA; McNeil SE
Expert Opin Drug Deliv; 2015 Jul; 12(7):1163-75. PubMed ID: 25994601
[TBL] [Abstract][Full Text] [Related]
20. Macrophage targeted nanocarrier delivery systems in HIV therapeutics.
Khan T; Mayuresh Patkar M; Momin M; Omri A
Expert Opin Drug Deliv; 2020 Jul; 17(7):903-918. PubMed ID: 32347124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
